The plaintiffs say they suffered unnecessary kidney and bone damage from taking one of Gilead's drugs, which could have swapped out an ingredient for a safer alternative. OAKLAND, Calif. (CN) — The ...
Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...
The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
FOSTER CITY, Calif., February 19, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback